Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Preferred Stock Liabilities: 2022-2024

Historic Preferred Stock Liabilities for Insight Molecular Diagnostics (IMDX) over the last 1 years, with Mar 2024 value amounting to $5.3 million.

  • Insight Molecular Diagnostics' Preferred Stock Liabilities was N/A to $5.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $5.3 million, marking a year-over-year change of. This contributed to the annual value of $5.1 million for FY2023, which is 3.32% down from last year.
  • According to the latest figures from Q1 2024, Insight Molecular Diagnostics' Preferred Stock Liabilities is $5.3 million, which was up 4.02% from $5.1 million recorded in Q4 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Preferred Stock Liabilities peaked at $5.3 million during Q1 2024, and registered a low of $4.7 million during Q2 2023.
  • Moreover, its 3-year median value for Preferred Stock Liabilities was $5.1 million (2022), whereas its average is $5.1 million.
  • Data for Insight Molecular Diagnostics' Preferred Stock Liabilities shows a maximum YoY fell of 3.32% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Insight Molecular Diagnostics' Preferred Stock Liabilities stood at $5.3 million in 2022, then declined by 3.32% to $5.1 million in 2023, then reached $5.3 million in 2024.
  • Its Preferred Stock Liabilities was $5.3 million in Q1 2024, compared to $5.1 million in Q4 2023 and $4.9 million in Q3 2023.